Blue Trust Inc. Decreases Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Blue Trust Inc. lessened its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 62.5% during the 4th quarter, Holdings Channel.com reports. The firm owned 538 shares of the medical equipment provider’s stock after selling 896 shares during the quarter. Blue Trust Inc.’s holdings in Lantheus were worth $48,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in LNTH. Janus Henderson Group PLC boosted its holdings in shares of Lantheus by 7.7% in the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock valued at $393,844,000 after buying an additional 257,022 shares in the last quarter. Geode Capital Management LLC lifted its position in Lantheus by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after acquiring an additional 32,551 shares during the last quarter. Reinhart Partners LLC. lifted its position in Lantheus by 9.9% during the fourth quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock valued at $122,280,000 after acquiring an additional 123,282 shares during the last quarter. Swedbank AB boosted its stake in Lantheus by 53.3% in the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock valued at $99,054,000 after acquiring an additional 385,000 shares in the last quarter. Finally, Portolan Capital Management LLC boosted its position in shares of Lantheus by 6.1% in the 3rd quarter. Portolan Capital Management LLC now owns 670,881 shares of the medical equipment provider’s stock worth $73,629,000 after purchasing an additional 38,776 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.50% of the company’s stock.

Lantheus Stock Up 1.4 %

Lantheus stock opened at $80.07 on Wednesday. The stock has a 50-day moving average price of $89.77 and a 200 day moving average price of $96.81. The company has a market capitalization of $5.57 billion, a price-to-earnings ratio of 13.32 and a beta of 0.44. Lantheus Holdings, Inc. has a 52 week low of $56.44 and a 52 week high of $126.89.

Wall Street Analysts Forecast Growth

LNTH has been the topic of several recent analyst reports. Truist Financial reaffirmed a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. JMP Securities restated a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Finally, The Goldman Sachs Group started coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $131.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.